Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 24, 2004. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 23, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 900,000 ordinary shares
- Price Per Share: 1,133.243 pence
- Transaction Purpose: Purchase for cancellation
Material Changes
The filing reports a reduction in the company's outstanding share count due to the cancellation of 900,000 shares. No other material changes to operations or financial position are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. The document is strictly a notification of the share repurchase execution.
Investor Verification Checklist
- Verify the total number of shares repurchased and cancelled to date under the May 2003 authorization.
- Confirm the total capital expenditure for this specific tranche of 900,000 shares.
- Review the company's full annual or interim reports for comprehensive financial performance data not included in this 6-K.